


## Introduction – Hypertriglyceridemia<sup>1</sup>

### Lipid profile




**> 2 mmol / L**  
**Hypertriglyceridemia**

<sup>1</sup>Gibbons RJ et Al. J Am Coll Cardiol. 2003 Jan 1;41(1):159-68.




## Introduction – Complications<sup>1</sup>




<sup>1</sup>Marik PE. Crit Care Clin. 2006 Jan;22(1):151-9



## Introduction – Risk factors



## Method – NUTSIA<sup>1</sup>



<sup>1</sup>Longchamps C. et Al. Rev Med Suisse. 2007 Dec 12;3(137):2844-8.

## Method – Measures

**Inclusion**

- ICU stay  $\geq$  4 days

**Exclusion**

- One determination of TG
- Oral feeding

**Calculation of delta-TG**

Lowest TG value      Highest TG value

Dynamic measure

Time	Triglycerides (mmol/l)
D1	1.5
D3	1
D5	1.2
D8	3

TG: Triglyceridemia

## Method – Measures

MetaVision Suite  
Query Wizard


**Patient data**

- Age
- Admission weight
- BMI
- Type of admission
- Diagnosis
- Mortality (ICU + Hosp)
- Recorded medications

**Laboratory data**

- ALAT
- ASAT
- Albumin
- Amylase
- Direct bilirubin
- Creatinine
- $\gamma$ -GT
- Glycemia
- Lipase
- Alkaline phosphatase
- Procalcitonin
- CRP
- Thromboplastin time
- Urea

Triglycerides, cholesterol, and HDL-cholesterol were analyzed as independent variables



## Results – Severity

Variables	All (n=220)	NormoTG (n=121)	HyperTG (n=99)	p-Value
Peak triglycerides (mmol/L)	1.9 [1.4 ; 2.9]	<b>1.5 [1.1 ; 1.7]</b>	<b>3 [2.6 ; 3.9]</b>	<0.001
Reference TG (mmol/L)	1.2 [0.8 ; 1.7]	<b>0.9 [0.7 ; 1.2]</b>	<b>1.7 [1.35 ; 2.3]</b>	<0.001
Delta TG (ref-peak) (mmol/L)	0.7 [0.4 ; 1.3]	<b>0.5 [0.3 ; 0.6]</b>	<b>1.3 [0.9 ; 1.9]</b>	<0.001
Time in ICU before peak (days)	7 [4 ; 9]	7 [4 ; 9]	7 [4.8 ; 9]	NS
HDL-Cholesterol (mmol/L)	0.6 [0.3 ; 0.9]	0.8 [0.5 ; 1.1]	0.4 [0.2 ; 0.7]	<0.05
Total Cholesterol (mmol/L)	3.5 [2.6 ; 4.2]	3.3 [2.5 ; 4]	3.7 [2.7 ; 4.7]	NS

Results presented as median [interquartile range]

hyperTG patients have higher reference TG values ( but within normal values)

Delta TG is higher in the hyperTG group

hyperTG: hypertriglyceridemia; normoTG: normotriglyceridemia

## Results – Risk factors

Peak triglyceride concentration correlated with...


Parameter term	Pearson's coefficient ( $r^2$ )	p-Value
<b>Propofol (mg/kg/hour)</b>	<b>0.28</b>	<b>&lt;0.001</b>
<b>Lipids from propofol (g/kg/j)</b>	<b>0.26</b>	<b>&lt;0.001</b>
<b>CRP (mg/L)</b>	<b>0.19</b>	<b>0.004</b>
Total lipid intake (g/kg/day)	0.14	0.024
Cumulative glucose intake (g/day)	0.12	NS
(g/kg/day)	0.11	NS
Cumulative energy intake (kcal/kg/day)	0.09	NS
LCT + MCT parenteral lipids (g/kg/day)	0.07	NS
Total LCT intake (g/kg/j)	0.04	NS
LCT + MCT enteral lipids (g/kg/day)	0.04	NS
Insuline dose (UI/24h)	0.02	NS

Sepsis was highly significantly associated with this metabolic alteration

LCT: Long chain triglycerides; MCT: Medium chain triglycerides



## Results – Risk factors



HyperTG occurred after:


- 7 days (as a median)
- 4 days (as a median) on higher dose propofol

Relationship existing between the propofol dose/day and the lipid dose/day

hyperTG: hypertriglyceridemia; normoTG: normotriglyceridemia



## Results – Risk factors



The observed changes in TG levels were not a unified process, but the conjunction of infection and high-dose propofol was a frequent pattern



## Results – Risk factors

### Propofol intake

- 144 patients (65.5%)
- Received before peak TG value: 0.04 to 5.83 mg/IBW/h
- Median dose associated with hyperTG: 2.04 mg/kg/h



### The magnitude of the TG increase ( $\Delta$ TG) was influenced by

- The cumulated dose of propofol before the peak ( $r^2=0.038$ ,  $p=0.0037$ )
- The propofol dose (mg/kg/h) ( $r^2=0.061$ ,  $p=0.0002$ )

### But less by

- the number of days on propofol before the peak ( $r^2=0.020$ ,  $p=0.034$ )
- The lipid dose ( $r^2=0.027$ ,  $p=0.013$ )

Total cholesterol and HDL-cholesterol levels were unaffected by the propofol dose

TG: triglyceridemia



## Conclusion – What?

### Nonsignificant risk factors....

#### Pathologies and drugs

- Except sepsis and propofol, nothing significant in this study

#### Nutrition

- No hyperalimentation observed in this study (lipid or glucose)

### Finally hypertriglyceridemia observed....

#### Infection

- Impact of the acute-phase response on the lipid metabolism



#### Propofol

- Lipid associated with propofol?
- Action on the mitochondria?



## Conclusion – How?

### Cumulative doses control

MetaVisionSuite  
Version 5.46.30 (Hostie-29)

200 mg/h of propofol intake during 24 hours corresponding to a lipid intake of

- 24g with 2% propofol
- 48g with 1% propofol

This corresponds to  $\frac{1}{4}$  to  $\frac{1}{2}$  of the recommended daily lipids intake

### Patients monitoring

#### Infection + propofol

- TG monitoring at least 2-3 times weekly



TG: Triglyceridemia

## What's Next?

Where are the costs?



PHARMAECONOMY  
of propofol



END 2013

EVOLUTION  
OF LIPIDS  
LIPIDS IN  
EVOLUTION



MIDDLE 2014

